High-throughput compound library construction and screening method and reaction device

By conducting 1,3-dipolar cyclization reactions in an independently addressable reaction chamber, compound libraries can be directly constructed and screened, solving the problems of inefficient synthesis of azide compounds and cumbersome construction of compound libraries in existing technologies, and achieving efficient construction and screening of compound libraries.

CN112176418BActive Publication Date: 2024-11-29DIPU SHENHE PHARMACEUTICAL R&D (SHANGHAI) CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN201910605212.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-07-05
Publication Date
2024-11-29
Estimated Expiration
2039-07-05

AI Technical Summary

Technical Problem

Existing methods for synthesizing azide compounds are inefficient, difficult to synthesize and use, and the construction and screening of compound libraries are cumbersome, making it difficult to carry out high-efficiency and high-throughput synthesis.

Method used

A reactor containing multiple independently addressable reaction chambers was used to synthesize a compound library via a 1,3-dipolar cyclization reaction, and the activity was directly tested in the reaction chambers, avoiding separation and purification steps.

Benefits of technology

It enables efficient and high-throughput compound library construction and screening, shortens the drug lead compound discovery cycle, and improves screening speed.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002120477930000031
    Figure BDA0002120477930000031
  • Figure BDA0002120477930000041
    Figure BDA0002120477930000041
  • Figure BDA0002120477930000051
    Figure BDA0002120477930000051
Patent Text Reader

Abstract

The present invention provides a high-throughput compound library construction and screening method and a reaction device. Specifically, the method of the present invention comprises: (a) providing a reactor, the reactor comprising n independently addressable reaction chambers; (b) in the n reaction chambers, m independently synthesizing reactions are performed to construct a compound library; and (c) in the reaction chambers where the synthesizing reactions are performed, an activity test is performed. In the present invention, the preparation and screening process of the compound can be completed in the same reaction system. Since the reactions of the present invention generate products almost quantitatively, the products can be directly used for activity test experiments in enzymology and even cytology without separation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of chemistry and biology, and in particular to a high-throughput compound library construction and screening method and a reaction device. Background Art

[0002] Triazole is an important five-membered nitrogen heterocyclic compound, which involves a wide range of industrial applications, such as agricultural chemicals, corrosion inhibitors, dyes, fluorescent whitening agents, and bioactive agents. Azide functional groups have extremely important and extensive uses in organic synthesis, but since these compounds have high energy, there are great safety hazards during synthesis, storage, and transportation, which makes them difficult to synthesize and use. The methods currently available to humans for synthesizing azide compounds are very limited. Most of the alkyl, acyl, and sulfonyl azides are obtained by nucleophilic substitution reactions using NaN3 to replace the leaving functional group in a polar solvent. This method requires separation and purification, and the synthesis efficiency is not high, resulting in cumbersome post-processing when used for further activity screening.

[0003] In the development of drugs and agricultural chemicals, people have screened commercial compound libraries and compound libraries produced by combinatorial synthesis in order to find physiologically active substances (such as lead compounds). However, in the synthesis of compounds used as drugs, separation and purification take a lot of time, and it is also difficult to find lead compounds that can be used as drugs. The compound library produced by combinatorial chemistry is a mixture of many compounds, and the product structure is difficult to control. In addition, in order to establish a compound library, we need to identify the structure of the compound in the process of synthesizing the compound and its derivatives, so as to determine the method suitable for modifying the compound and explore the reaction conditions for synthesizing the derivatives. The disadvantage of this is that it takes a lot of time to synthesize the compound.

[0004] Therefore, it is necessary to develop a simple, efficient, and high-throughput method for synthesizing compound libraries and performing activity screening. Summary of the invention

[0005] The invention provides a simple, efficient and high-throughput method for synthesizing a compound library and performing activity screening.

[0006] In a first aspect, the present invention provides a method for constructing and screening a high-throughput compound library, comprising:

[0007] (a) providing a reactor, the reactor comprising n reaction chambers, wherein the reaction chambers are each independent and addressable, and the n reaction chambers constitute an addressable reaction chamber array;

[0008] (b) performing m independent synthesis reactions in the n reaction chambers, and obtaining synthesis products in each reaction chamber for performing the synthesis reaction, thereby constructing a compound library;

[0009] Wherein, the synthetic reaction comprises the following steps:

[0010] (b1) in a reaction chamber, in an inert solvent, reacting a 1,3-dipolar cyclization reagent with a reaction substrate containing a terminal unsaturated bond to undergo a 1,3-dipolar cycloaddition reaction to form a reaction product containing a 1,3-dipolar ring;

[0011] and (c) optionally, adding activity test reagents to the reaction chambers where the synthesis reaction is performed, respectively, to perform activity tests, thereby performing activity screening on each synthesis product;

[0012] Wherein, n is a positive integer ≥10, and m is a positive integer ≤n and m≥10.

[0013] In another preferred embodiment, in step (c), after adding the activity test reagent, incubation is performed to allow the activity test reagent to react or contact with each synthesis reaction.

[0014] In another preferred embodiment, the reactor comprises an array reactor.

[0015] In another preferred embodiment, n is 20-50000, preferably 36-10000, more preferably 48-5000, and most preferably 96-2500.

[0016] In another preferred embodiment, the 1,3-dipolar cyclization reagent is R-N3, wherein R is a molecular part (moiety) or a fragment connected to the azide group.

[0017] In another preferred embodiment, the same synthesis reaction is carried out in two or more reaction chambers.

[0018] In another preferred embodiment, different synthesis reactions are carried out in each reaction chamber.

[0019] In another preferred embodiment, in the synthesis reaction, m types of 1,3-dipolar cyclization reagents respectively located in m reaction chambers are used to react with the same type of reaction substrate containing a terminal unsaturated bond.

[0020] In another preferred embodiment, the "terminal unsaturated bond" refers to the existence of a double bond or a triple bond between the terminal atom (excluding hydrogen atom) at the terminal and its adjacent second terminal atom (excluding hydrogen atom).

[0021] In another preferred embodiment, the terminal atom and the sub-terminal atom are independently selected from the following group: C, N, or a combination thereof.

[0022] In another preferred embodiment, the "terminal unsaturated bond" is selected from the following group: C=C, C≡C, C≡N, or a combination thereof.

[0023] In another preferred embodiment, the reaction chamber is a micro or small reaction chamber.

[0024] In another preferred embodiment, the volumes of the reaction chambers are independently 5 μL-5000 μL.

[0025] In another preferred embodiment, the volume of the reaction chamber is 10-2000 μL, more preferably 20 μL-1500 μL.

[0026] In another preferred embodiment, in a single reaction chamber, the volume of the reaction system for performing the synthesis reaction is ≤2 ml, preferably ≤1 ml, and more preferably ≤0.6 ml.

[0027] In another preferred embodiment, in a single reaction chamber, the volume of the reaction system for performing the synthesis reaction is 5-2000 μL, preferably 10-1000 μL, and more preferably 20-600 μL.

[0028] In another preferred embodiment, the activity test reagent is selected from the following group: small molecule compounds, proteins, nucleic acids, cells, or a combination thereof.

[0029] In another preferred embodiment, the activity test reagent comprises an enzyme activity test reagent composition or a cell activity test reagent composition.

[0030] In another preferred embodiment, the activity test reagent is a compound with physiological activity, preferably selected from the following group: enzyme inhibitors, ligand / receptor binding inhibitors, angiogenesis inhibitors, cell adhesion inhibitors, gene expression inhibitors and growth factor-like active substances.

[0031] In another preferred embodiment, the enzyme inhibitor is selected from the following group: tyrosinase inhibitors, epoxide and enzyme inhibitors, telomerase inhibitors, matrix metalloproteinase inhibitors, prostaglandin D synthesis inhibitors, phosphodiesterase inhibitors, cholinesterase inhibitors, viral protease inhibitors, reverse transcriptase inhibitors, or a combination thereof.

[0032] In another preferred embodiment, the protein includes: an antibody, a ligand, an antigen, or a combination thereof.

[0033] In another preferred embodiment, the step (c) includes the step of detecting each reaction chamber, thereby obtaining the activity test results in each chamber respectively.

[0034] In another preferred embodiment, the steps between steps (b) and (c) do not include a step of separating or purifying the reaction product.

[0035] In another preferred embodiment, after step (b) (eg, step (b1)), the sample is directly used in step (c) for subsequent activity testing without separation.

[0036] In another preferred embodiment, in the step (b), the reaction formula of the 1,3-dipolar cycloaddition reaction is selected from the following group:

[0037]

[0038] In the formula, R, R', R" and R"' are each independently R 1 or The R 1 and R 2 Each is independently a substrate fragment.

[0039] In another preferred embodiment, in the step (b), the reaction formula of the 1,3-dipolar cycloaddition reaction is as follows:

[0040]

[0041] Wherein, R and R" are each independently R 1 or The R 1 and R 2 Each is independently a substrate fragment.

[0042] In another preferred embodiment, the R 1 and R 2 It is the remaining molecular parts of the reaction substrate except the molecular part (moiety) of the terminal unsaturated bond.

[0043] In another preferred embodiment, the R 1 and R 2 Each is independently a pharmaceutically active fragment.

[0044] In another preferred embodiment, the R 1 and R 2 Each is independently substituted or unsubstituted and is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, heterocyclyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaromatic, sulfonyl, or a combination thereof.

[0045] In another preferred embodiment, the R 1 and R 2 Each independently selected from the following group: substituted or unsubstituted C1-C 12alkyl, substituted or unsubstituted 3-12 membered heteroalkyl, substituted or unsubstituted 5-16 membered heteroaryl, substituted or unsubstituted C6-C 18 aryl, substituted or unsubstituted 3-20 membered heterocyclic group, substituted or unsubstituted C3-C 12 wherein the substitution refers to that one or more hydrogen atoms in the group are replaced by a substituent Ra, and the Ra is selected from the group consisting of halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C 12 Cycloalkyl, oxo (i.e., =O), Rf-SO2-, =NRf, -CN, hydroxyl, -ORf, NRdRe, substituted or unsubstituted C1-C6 amine, substituted or unsubstituted -(C1-C6 alkylene)-NH-(C1-C6 alkylene), carboxyl, substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted 5-12-membered heteroaryl having 1-3 heteroatoms, substituted or unsubstituted 5-12-membered heterocyclic group having 1-4 heteroatoms, wherein the substituent is selected from the following group: halogen, hydroxyl, carboxyl, cyano, C1-C6 alkoxy, C1-C6 alkylamino;

[0046] Rd, Re, and Rf are each independently selected from the group consisting of H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted 5-12-membered heteroaryl having 1-3 heteroatoms, substituted or unsubstituted 5-12-membered heterocyclyl having 1-4 heteroatoms;

[0047] The "substituted" of Ra, Rd, Re, and Rf refers to being substituted by one or more (e.g., 2, 3, 4, etc.) substituents selected from the group consisting of halogen, -CH2Cl, -CHCl2, -CCl3, -CH2F, -CHF2, -CF3, -O(CH2) x O(CH2) y CH3, oxo, -CN, hydroxyl, amino, substituted amine, carboxyl, -NHAc, a group selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C6-C 10 Aryl, C3-C8 cycloalkyl, halogenated C6-C 10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O;

[0048] x is 1, 2, 3, 4, 5, or 6;

[0049] y is 0, 1, 2, 3, 4, 5, or 6;

[0050] In the above formulae, any of the heteroatoms are independently selected from the group consisting of N, S and O.

[0051] In another preferred embodiment, any reaction substrate and reaction product or each group or atom therein complies with the relevant rules for the valence state of the compound (for example, the highest valence state of C is 4, and the highest valence state of N is 5).

[0052] In another preferred embodiment, the reaction substrate and reaction product are organic compounds.

[0053] In another preferred embodiment, the R-NH2 is an unprotected free amine or a salt of an acid-protected amine.

[0054] In another preferred embodiment, the 1,3-dipolar cycloaddition reaction is a modular synthesis using the principle of click chemistry reaction.

[0055] In another preferred embodiment, the 1,3-dipolar cyclization reagent is prepared in situ or added to the reaction chamber.

[0056] In another preferred embodiment, the step (b), before step (b1), further comprises:

[0057] (b0) reacting an amine fragment (preferably R-NH2) with FSO2N3 in an inert solvent in the presence of a base to prepare a 1,3-dipolar cyclization reagent;

[0058]

[0059] Wherein, R is a molecular part (moiety) or a fragment connected to the azide group.

[0060] In another preferred embodiment, the step (b0) is performed in or not in the reaction chamber.

[0061] In another preferred embodiment, in the step (b0), m different amines respectively located in m reaction chambers are used to react with FSO2N3 respectively, so as to obtain different R-N3.

[0062] In another preferred embodiment, the molar ratio of R-NH2 to FSO2N3 is preferably about 1:2 to 2:1, such as about 1:1.

[0063] In another preferred embodiment, the molar ratio of the base to FSO2N3 is about 10:1 to 2:1, preferably about 4:1.

[0064] In another preferred embodiment, in the step (b0), the azide compound preparation reaction can be carried out at 0°C to 60°C, preferably 25°C to 30°C.

[0065] In another preferred embodiment, the azide compound R-N3 prepared in step (b0) is directly used in the subsequent 1,3-dipolar cycloaddition reaction without isolation.

[0066] In another preferred embodiment, in step (b) (including step (b0) and / or step (b1)), the inert solvent is selected from the following group: water, nitrile solvents, alcohol solvents, aromatic hydrocarbon solvents, halogenated alkane solvents, sulfur dioxide, alkane solvents, ester solvents, ketone solvents, ether solvents, sulfoxide solvents, amide solvents and N-methylpyrrolidone, or a combination thereof.

[0067] In another preferred embodiment, the nitrile solvent is acetonitrile.

[0068] In another preferred embodiment, the alcohol solvent is selected from the following group: methanol, ethanol, tert-butanol, or a combination thereof.

[0069] In another preferred embodiment, the aromatic hydrocarbon solvent is selected from the following group: benzene, toluene, trifluorotoluene, fluorobenzene, or a combination thereof.

[0070] In another preferred embodiment, the halogenated alkane solvent is selected from the following group: dichloromethane, chloroform, 1,2-dichloroethane, or a combination thereof.

[0071] In another preferred embodiment, the alkane solvent is selected from the following group: petroleum ether 30-60, petroleum ether 60-90, n-hexane, or a combination thereof.

[0072] In another preferred embodiment, the ester solvent is ethyl acetate.

[0073] In another preferred embodiment, the ketone solvent is acetone.

[0074] In another preferred embodiment, the ether solvent is selected from the following group: methyl tert-butyl ether, 1,4-dioxane, diethyl ether, tetrahydrofuran, or a combination thereof.

[0075] In another preferred embodiment, the sulfoxide solvent is dimethyl sulfoxide.

[0076] In another preferred embodiment, the amide solvent is N,N-dimethylformamide.

[0077] In another preferred embodiment, the solvent is a mixed solvent of an ether solvent, a sulfoxide solvent and water, or a mixed solvent of an ether solvent, a nitrile solvent and water.

[0078] In another preferred embodiment, the solvent is a mixed solvent of methyl tert-butyl ether, dimethyl sulfoxide and water, or a mixed solvent of methyl tert-butyl ether, acetonitrile and water.

[0079] In another preferred embodiment, when the solvent is a mixed solvent of an ether solvent, a sulfoxide solvent and water, the volume ratio of the ether solvent, the sulfoxide solvent and water is 2-7:10-20:0.8-1.2; preferably 5:15:1.

[0080] In another preferred embodiment, when the solvent is a mixed solvent of an ether solvent, a nitrile solvent and water, the volume ratio of the mixed solvent of the ether solvent, the nitrile solvent and water is 15-25:0.8-1.2:15-25; preferably 20:1:20.

[0081] In another preferred embodiment, in step (b) (including step (b0) and / or step (b1)), the base is an inorganic base and / or an organic base.

[0082] In another preferred embodiment, when the base is an inorganic base, the inorganic base is one or more of sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate and potassium phosphate.

[0083] In another preferred embodiment, when the base is an organic base, the organic base is one or more of triethylamine, N,N-diisopropylethylamine, pyrrole, pyridine, 4-dimethylaminopyridine, sodium acetate, potassium acetate, sodium methoxide, sodium ethoxide, potassium tert-butoxide, 1,8-diazabicycloundec-7-ene and tetramethylethylenediamine.

[0084] In another preferred embodiment, the method further comprises:

[0085] The reaction substrate, reaction product, and activity test data are associated based on the addressable addresses of the reaction chamber to obtain an addressable data set.

[0086] In a second aspect of the present invention, there is provided a high-throughput addressable reaction device, the device comprising:

[0087] (i) a reaction module, wherein the reaction module is used to perform a 1,3-dipolar cycloaddition reaction; and the reaction module comprises at least one reactor, wherein the reactor comprises n reaction chambers, wherein the reaction chambers are each independent and addressable, and the n reaction chambers constitute an addressable reaction chamber array, and the reaction chamber is used to perform the 1,3-dipolar cycloaddition reaction, thereby forming a synthetic product in the reaction chamber;

[0088] Wherein, n is a positive integer ≥ 10, m is a positive integer ≤ n and m ≥ 10;

[0089] and (ii) an optional activity testing module, wherein the activity testing module is used to perform an activity test on the synthesis product formed in the reaction chamber in situ, thereby obtaining activity testing data.

[0090] In another preferred embodiment, the reactor comprises m reaction reagents, which are respectively located in m reaction chambers; wherein the reaction reagent is a 1,3-dipolar cyclization reagent or an amine precursor thereof (ie, an amine fragment).

[0091] In another preferred embodiment, the device further comprises (iii) an automatic pipetting module, wherein the automatic pipetting module is used to add reaction reagents and / or activity test reagents into predetermined addressable reaction chambers.

[0092] In another preferred embodiment, the device further comprises: (iv) a processor, wherein the processor is used to control one or more modules among the reaction module, the activity test module, and the automatic pipetting module.

[0093] In another preferred embodiment, the processor is further used to associate the reaction substrate, reaction product, and activity test data based on the addressable address of the reaction chamber to obtain an addressable data set, and send or store the data set.

[0094] In another preferred embodiment, the reactor is selected from the following group: a microplate, an array PE tube, an array test tube, an array reaction bottle, or a combination thereof.

[0095] In another preferred embodiment, the reactor is an array reactor.

[0096] In a third aspect, the present invention provides a method for constructing a compound library, comprising the steps of:

[0097] (1) Using the high-throughput addressable reaction device described in the second aspect to construct the compound library.

[0098] In another preferred embodiment, step (1) includes the following steps:

[0099] (1a) when the reaction reagent is an amine fragment, reacting FSO2N3 with the amine fragment compound in each reaction chamber to prepare a 1,3-dipolar cyclization reagent, thereby obtaining a first compound library consisting of a 1,3-dipolar cyclization reagent; and

[0100] (1b) Optionally, in the reaction chamber, a reaction substrate containing a terminal unsaturated bond is reacted with the 1,3-dipolar cyclization reagent to form a 1,3-dipolar ring compound, thereby obtaining a second compound library consisting of the 1,3-dipolar ring compounds.

[0101] In another preferred embodiment, the method further comprises:

[0102] (2) Conducting an activity test on the 1,3-dipolar ring compounds in the second compound library in situ in the reaction chamber.

[0103] In a fourth aspect, the present invention provides a use of the high-throughput addressable reaction device according to the second aspect, for one or more uses selected from the following group:

[0104] a) Synthesize different compounds simultaneously;

[0105] b) High-throughput (HTS) random screening of compounds with physiological activity;

[0106] c) the search for pharmaceuticals or agricultural chemicals; and

[0107] d) Searching for lead compounds of drugs or agricultural chemicals.

[0108] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0109] Figure 1 The preparation of a library of 1224 azide compounds and a library of 1224 triazole compounds from a library of primary amine compounds is shown.

[0110] Figure 2a -f shows an exemplary UPLC chromatogram of the preparation of the azide compound library from the primary amine compound library.

[0111] Figure 3a -f shows an exemplary UPLC chromatogram of azide library subjected to copper-catalyzed cycloaddition reaction (CuAAC) of terminal azide alkynes (4a).

[0112] Figure 4a -i shows an exemplary UPLC chromatogram of a primary amine compound library directly obtaining a 1,2,3-triazole compound library via diazo transfer and copper-catalyzed cycloaddition reaction (CuAAC) of terminal azide alkynes (4a).

[0113] Figure 5a -d shows an exemplary UPLC chromatogram of a primary amine compound library directly obtaining a 1,2,3-triazole compound library via diazo transfer and copper-catalyzed cycloaddition (CuAAC) of terminal azide alkynes (4b).

[0114] Figure 6It shows that in one embodiment of the present invention, a compound library containing 840 compounds was constructed for a drug molecule in a high-throughput manner and activity screening was performed. DETAILED DESCRIPTION

[0115] Through extensive and in-depth research, the inventors have developed for the first time a high-throughput compound library construction and screening method and a device for the method. In the method of the present invention, an addressable reaction chamber array consisting of multiple independent and addressable reaction chambers is used for the first time, and specific synthetic reactions are independently performed in each reaction chamber, so as to obtain a large number of different reaction products with clear structures at high throughput, and thus obtain a high-throughput compound library. Unexpectedly, experiments show that the addressable reaction chamber array (or corresponding compound library) containing the reaction products can be directly used in situ to perform subsequent compound activity determination without separation and purification, thereby greatly improving the efficiency of compound library construction and screening. The present invention was completed on this basis.

[0116] In a preferred embodiment, the inventors use an addressable reaction chamber array to synthesize thousands of different 1,3-dipole cyclization reagents (as an azide compound library, or a first compound library) at high throughput, and then synthesize thousands of different 1,3-dipole cyclization reaction products (as a triazole derivative library, or a second compound library) at high throughput. By performing in situ activity screening on the compound library of the present invention, the discovery of drug lead compounds is greatly accelerated, the screening speed is increased, and the development research cycle of new inhibitors is shortened (from several years to several weeks or days).

[0117] the term

[0118] The "reaction chamber" used in the present invention refers to various devices capable of performing chemical reactions, including but not limited to: micropores of a microplate, PE tubes, test tubes, reaction bottles, and the like.

[0119] Definitions of standard chemical terms can be found in references including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4THED." Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods within the skill of the art, such as mass spectrometry, NMR, IR and UV / VIS spectroscopy and pharmacological methods, are used. Unless specifically defined, the terms used herein in the descriptions of analytical chemistry, organic synthetic chemistry, and pharmaceutical and medicinal chemistry are known in the art. For example, the manufacturer's instructions for use of the kit may be used, or the reactions and purifications may be carried out in a manner known in the art or in accordance with the descriptions of the present invention. The above techniques and methods may generally be implemented in accordance with conventional methods well known in the art, based on the descriptions in the multiple general and more specific references cited and discussed in this specification. In this specification, groups and substituents thereof may be selected by those skilled in the art to provide stable structural moieties and compounds.

[0120] When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents that would result if the formula were written from right to left. For example, -CH2O- is equivalent to -OCH2-.

[0121] The section headings used herein are only for the purpose of organizing the article and should not be interpreted as limitations on the subject matter described. All documents or portions of documents cited in this application, including but not limited to patents, patent applications, articles, books, operating manuals and papers, are incorporated herein by reference in their entirety.

[0122] Certain chemical groups defined herein are preceded by simplified symbols to indicate the total number of carbon atoms present in the group. For example, a C1-C6 alkyl group refers to an alkyl group as defined below having a total of 1 to 6 carbon atoms. The total number of carbon atoms in the simplified symbols does not include carbons that may be present in substituents of the group.

[0123] In addition to the foregoing, when used in the specification and claims of the present application, the following terms have the meanings indicated below unless otherwise specifically stated.

[0124] In the present application, the term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0125] "Hydroxyl" refers to -OH.

[0126] "Carbonyl" refers to -C(=O)-.

[0127] "Cyano" refers to -CN.

[0128] "Amino" refers to -NH2.

[0129] "Substituted amino" refers to an amino group substituted with one or two alkyl groups, alkylcarbonyl groups, aralkyl groups, heteroaralkyl groups as defined below, for example, monoalkylamino, dialkylamino, alkylacylamino, aralkylamino, heteroaralkylamino.

[0130] "Carboxyl" refers to -COOH.

[0131] In the present application, as a group or as part of other groups (e.g., in groups such as halogen-substituted alkyl), the term "alkyl" refers to a fully saturated straight or branched hydrocarbon chain radical consisting only of carbon atoms and hydrogen atoms, having, for example, 1 to 12 (preferably 1 to 8, more preferably 1 to 6) carbon atoms, and connected to the rest of the molecule by a single bond, such as, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, heptyl, 2-methylhexyl, 3-methylhexyl, octyl, nonyl and decyl, etc. Examples of cycloalkyl include monocyclic or polycyclic alkyls such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, etc.

[0132] "Alkylene" used alone or in compound words such as optionally substituted alkylene means the same groups as "alkyl" defined above, except that another hydrogen is removed to form a divalent group. It should be understood that the optional substituents may be attached to the alkylene chain or form part of the alkylene chain.

[0133] "Alkenyl" used alone or in compound words such as "optionally substituted alkenyl" means a radical formed from a straight chain, branched chain or cyclic olefin, including ethylenically mono-, di- or polyunsaturated alkyl or cycloalkyl as defined above, preferably C2-6 alkenyl. Examples of alkenyl groups include vinyl, allyl, 1-methylvinyl, butenyl, isobutenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3-heptenyl, 1-octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3 cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3 cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl, and 1,3,5,7-cyclooctatetraenyl.

[0134] "Alkynyl" used alone or in compound words such as "optionally substituted alkynyl" means a radical formed from a straight chain, branched chain or mono-, di- or polycyclic alkyne, preferably a C2-6 alkynyl. Examples of alkynyl include ethynyl, 1-propynyl, 1- and 2-butynyl, 2-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 10-undecynyl, 4-ethyl-1-octyn-3-yl, 7-dodecynyl, 9-dodecynyl, 10-dodecynyl, 3-methyl-1-dodecyn-3-yl, 2-tridecynyl, 11-tridecynyl, 3-tetradecynyl, 7-hexadecynyl, 3-octadecynyl, etc.

[0135] In the present application, as a group or as part of other groups, the term "heteroalkyl" means a fully saturated straight or branched hydrocarbon chain group consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. The nitrogen, carbon or sulfur atom in the heteroalkyl group may be optionally oxidized; the nitrogen atom may be optionally quaternized.

[0136] In the present application, as a group or part of other groups, the term "heterocyclyl" means a stable 3- to 20-membered non-aromatic cyclic group consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. Unless otherwise specified in this specification, the heterocyclyl can be a monocyclic, bicyclic, tricyclic or more ring system, which can include a fused ring system, a bridged ring system or a spiro ring system; the nitrogen, carbon or sulfur atoms in the heterocyclyl can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl can be partially or fully saturated. The heterocyclyl can be connected to the rest of the molecule via a carbon atom or a heteroatom and by a single bond. In a heterocyclyl containing a fused ring, one or more rings can be an aryl or heteroaryl group as defined below, provided that the point of connection with the rest of the molecule is a non-aromatic ring atom. For the purpose of the present invention, the heterocyclic group is preferably a stable 4- to 11-membered non-aromatic monocyclic, bicyclic, bridged or spirocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, and more preferably a stable 4- to 8-membered non-aromatic monocyclic, bicyclic, bridged or spirocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. Examples of heterocyclic groups include, but are not limited to, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, 2,7-diaza-spiro[3.5]nonan-7-yl, 2-oxa-6-aza-spiro[3.3]heptan-6-yl, 2,5-diaza-bicyclo[2.2.1]heptan-2-yl, azetidinyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrofuranyl, oxazinyl, dioxolane, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, quinolizinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, dihydroindolyl, octahydroindolyl, octahydroisoindolyl, pyrrolidinyl, pyrazolidinyl, phthalimido, and the like.

[0137] In the present application, the term "aryl" as a group or part of another group means a conjugated hydrocarbon ring system radical having 6 to 18 carbon atoms, preferably 6 to 10 carbon atoms. For the purposes of the present invention, aryl can be a monocyclic, bicyclic, tricyclic or more ring system, and can also be fused to a cycloalkyl or heterocyclic group as defined above, provided that the aryl is connected to the rest of the molecule by a single bond via an atom on the aromatic ring. Examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, 2,3-dihydro-1H-isoindolyl, 2-benzoxazolinone, 2H-1,4-benzoxazine-3(4H)-one-7-yl, and the like.

[0138] In the present application, as a group or part of other groups, the term "heteroaryl" means a 5- to 16-membered conjugated ring system group having 1 to 15 carbon atoms (preferably 1 to 10 carbon atoms) and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur in the ring. Unless otherwise specified in this specification, the heteroaryl group can be a monocyclic, bicyclic, tricyclic or more ring system, and can also be fused with a cycloalkyl or heterocyclic group as defined above, provided that the heteroaryl group is connected to the rest of the molecule through a single bond via an atom on the aromatic ring. The nitrogen, carbon or sulfur atoms in the heteroaryl group can be optionally oxidized; the nitrogen atom can be optionally quaternized. For the purpose of the present invention, heteroaryl is preferably a stable 5- to 12-membered aromatic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a stable 5- to 10-membered aromatic group containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, or a 5- to 6-membered aromatic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. Examples of heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, indolyl, furanyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indolizinyl, isoindolyl, indazolyl, isoindazolyl, purinyl, quinolyl, isoquinolyl, naphthazinyl, naphthyridinyl, quinoxalinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, phenanthrolinyl, acridinyl, phenazinyl, isothiazolyl, benzothiazolyl, benzothiophenyl, oxatriol, oxazolyl, cinnolinyl, quinazolinyl, phenylthio, indolizinyl, o-phenanthroline, isoxazolyl, phenoxazinyl, phenothiazinyl, 4,5,6,7-tetrahydrobenzo[b]thienyl, naphthopyridinyl, [1,2,4]triazolo[4,3-b]pyridazine, [1,2,4]triazolo[4,3-a]pyrazine, [1,2,4]triazolo[4,3-c]pyrimidine, [1,2,4]triazolo[4,3-a]pyridine, imidazo[1,2-a]pyridine, imidazo[1,2-b]pyridazine, imidazo[1,2-a]pyrazine, etc.

[0139] In the present application, "optionally" or "substituted or unsubstituted" means that the event or situation described subsequently may or may not occur, and the description includes both the occurrence and non-occurrence of the event or situation. For example, "optionally substituted aryl" means that the aryl is substituted or unsubstituted, and the description includes both substituted aryl and unsubstituted aryl. The "optionally" substituents described in the claims and the specification of the present invention are selected from alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, cyano, nitro, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.

[0140] As used herein, the terms "part", "moiety", "chemical moiety", "group", "chemical group" refer to a specific fragment or functional group in a molecule. A chemical moiety is generally considered to be a chemical entity embedded in or attached to a molecule.

[0141] Construction and application of compound library

[0142] In a preferred embodiment of the present invention, a CuAAC-based synthesis reaction is used to achieve chemical connection between two molecules, thereby constructing a compound library with high throughput.

[0143] Due to the simplicity and high efficiency of the method of the present invention, the diazo transfer can have certain industrial applicability even in a small laboratory. For example, in the case of obtaining 1000 primary amines, one person can construct a 1000 primary amine compound library with a concentration of 0.1 mol / L within 2 weeks, and the 1000 primary amine compounds can be azidated within one day to construct a 1000 azide compound library. The 1000 azide compounds can react with terminal alkynyl compounds. For example, 100 terminal alkynyl compounds can obtain 100,000 triazole compounds, which can be directly used for subsequent activity screening. Compared with conventional compound libraries generated by combinatorial chemistry, the compound library constructed by the present invention mainly contains one compound in each reactor, rather than a mixture of many compounds, and is easy to control.

[0144] The structures of the compounds in the library can be analyzed by any known structural analysis method, such as mass spectrometry, tandem mass spectrometry, UV / visible absorption spectroscopy, proton nuclear magnetic resonance spectroscopy, C 13 Nuclear magnetic resonance spectroscopy, infrared absorption spectroscopy and X-ray diffraction crystallography, or a combination of these.

[0145] The present invention provides a high-throughput compound library construction and screening method, which can synthesize different compounds in large quantities at one time. The constructed compound library can be used for high-throughput (HTS) random screening, the search for drugs or agricultural chemicals, the search for lead compounds of drugs or agricultural chemicals, etc.

[0146] For example, in order to obtain a compound with physiological activity, various screenings can be performed using the compound library. Examples of compounds with physiological activity include, but are not limited to, enzyme inhibitors, ligand / receptor binding inhibitors, angiogenesis inhibitors, cell adhesion inhibitors, gene expression inhibitors, and growth factor-like active substances. Examples of enzyme inhibitors include tyrosinase inhibitors, epoxide and enzyme inhibitors, telomerase inhibitors, matrix metalloproteinase inhibitors, prostaglandin D synthesis inhibitors, phosphodiesterase inhibitors, cholinesterase inhibitors, viral protease inhibitors, and reverse transcriptase inhibitors. Examples of receptors include adrenergic receptors, histamine receptors, leukotriene receptors, and opioid receptors.

[0147] 1,3-Dipole Cycloreductants

[0148] In the present invention, a 1,3-dipolar cyclization reaction is performed on a substrate fragment having an unsaturated bond at the end by a 1,3-dipolarizing agent to obtain a compound containing a 1,3-dipolar ring structure, such as a triazole compound. The exemplary reaction route is shown in the following formula:

[0149]

[0150] In the formula, R, R', R" and R"' are each independently R 1 or The R 1 and R 2 Each is independently a substrate fragment.

[0151] In the present invention, the R 1 and R 2 It is the remaining molecular parts of the reaction substrate except the molecular part (moiety) of the terminal unsaturated bond.

[0152] Preferably, the R 1 and R 2 Each is independently a pharmaceutically active fragment from a drug molecule.

[0153] In the present invention, for R, R', R" and R"' or the corresponding R 1 and R 2 There is no particular limitation and it can be any suitable organic group; typically, the representative R 1 and R 2 An organic group formed by elements such as C, H, O, N, S, F, Cl, etc., for example, a molecular part (moiety) composed of a substituted or unsubstituted group selected from the following groups: alkyl, cycloalkyl, heteroalkyl, heterocyclyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, sulfonyl, or a combination thereof.

[0154] Although the present invention cites exemplary R, ​​R', R", and R"' groups, it should be understood that under the method of the present invention, any compound with an azide structure can be used as the 1,3-dipolar cyclization reagent of the present invention to react with a substrate having an unsaturated group (such as an alkenyl group, an alkynyl group, a cycloalkenyl group, a cyano group, etc.) at the terminal to obtain a compound containing a nitrogen heterocycle.

[0155] A particularly preferred substrate is a drug molecule known in the art (e.g., erlotinib molecule), or a known drug molecule modified with an unsaturated group. In a preferred embodiment, the modification can be obtained by a method known in the art using a retrosynthetic analysis method to obtain a modification route, for example, by using a coupling reaction known in the art to modify the unsaturated group (e.g., Suzuki reaction, etc.).

[0156] 1,3-Dipolar Cyclization Reagents (Azides)

[0157] In the present invention, the azide compound used as a 1,3-dipolarizing agent can also be prepared by reacting an amine fragment with fluorosulfonyl azide. An exemplary reaction formula is as follows:

[0158]

[0159] Wherein the substituent R can be all substituted or unsubstituted alkyl, cycloalkyl, heteroalkyl, heterocyclic, alkenyl, cycloalkenyl, alkynyl, aryl, aromatic heteroyl, sulfonyl, or a combination thereof. For exemplary definitions of R, see the definitions of R, R', R" and R'" above.

[0160] Although the present invention provides exemplary R groups, it should be understood that under the method of the present invention, any substrate with a primary amine structure can be used as the amine fragment of the present invention to construct an azide compound as a 1,3-dipolar cyclization reagent. It should be understood that since there are abundant primary amine compounds in nature, the method can be carried out using any existing primary amine fragment, and any primary amine fragment developed subsequently can also be used.

[0161] The main advantages of the present invention include:

[0162] 1. The reaction is simple and efficient, and can rapidly and massively synthesize hundreds or thousands or more compounds with clear structures, thereby obtaining an addressable compound library.

[0163] 2. The 1,3-dipolar cyclization reagent compound library and the 1,3-dipolar ring reagent compound library can be quickly constructed.

[0164] 3. Compared with conventional compound libraries produced by combinatorial chemistry, the compound library constructed by the present invention mainly contains one compound in each reactor, rather than a mixture of multiple reaction products, and is easy to control.

[0165] 4. The high-throughput compound library construction and screening method of the present invention can be applied to fragment-based drug discovery because the stoichiometric reagents are almost quantitative.

[0166] 5. The high-throughput compound library construction and screening method of the present invention can be directly applied to activity research and even directly perform phenotypic screening, which is not achievable with previous combinatorial chemistry.

[0167] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0168] Example 1

[0169] Preparation of Fluorosulfonyl Azide (FSO2N3)

[0170]

[0171] In an ice bath, add 1-(fluorosulfonyl)-2,3-dimethyl-1H-imidazole trifluoromethanesulfonate in acetonitrile (6mmol, 1ml MeCN) to a mixture of sodium azide aqueous solution (0.25M, 20ml; containing 5mmol NaN3) and methyl tert-butyl ether (20ml). The reaction system was stirred in an ice bath for 10 minutes, and then the reaction solution was allowed to stand at room temperature (25°C) for 5 minutes. The aqueous phase in the reaction system was removed, and the organic phase obtained was fluorosulfonyl azide (FSO2N3) solution, with a yield of 92% (through 19 F NMR determination, relative to the number of moles of sodium azide used; in methyl tert-butyl ether (MTBE), the product has a chemical shift of +61.5 ppm and can be quantified using a known amount of The total amount of product in the reaction system is calculated by the integral ratio of the product and the internal standard signal in the fluorine spectrum, thereby calculating the reaction yield). GC-MS (tR): 1.69min; EI-MS (m / z): 125[M]+ (GC-MS (EI) spectrum was determined using Agilent 7890A GC System and Agilent 5975C Inert MSD system, method: T0 = 40°C, t = 10min, ramp = 20°C / min; T1 = 200°C, t = 10min). Dimethyl sulfoxide (DMSO, about 20ml) was added to the fluorosulfonyl azide (FSO2N3) solution, and the resulting solution can be directly used for the diazo transfer reaction of the primary amine compound (see Example 3).

[0172] Example 2 Preparation of primary amine compound library

[0173] 1128 different primary amine compounds (including alkyl primary amines, aryl primary amines and aromatic heterocyclic primary amines) were prepared into solutions with a concentration of about 100 mM, the solvent was dimethyl sulfoxide, the volume was about 1 ml, and stored in a 96-well microplate with a specification of 1.2 ml.

[0174] When the primary amine compound is an aryl primary amine or an aromatic heterocyclic primary amine, and the compound contains n primary amine functional groups that can be converted into azide, 0.10 / n mmol of the primary amine is dissolved in 1.0 ml of dimethyl sulfoxide in a 1.5 ml centrifuge tube, and then transferred to the corresponding wells of the corresponding microplate.

[0175] When the primary amine compound is an ammonium salt obtained by neutralizing an alkyl primary amine with hydrochloric acid, methanesulfonic acid, tartaric acid, p-toluenesulfonic acid or hydrobromic acid, and the compound contains n primary amine functional groups that can be converted into azide, 0.10 / n mmol of the primary amine is dissolved in 1.0 ml of dimethyl sulfoxide in a 1.5 ml centrifuge tube and then transferred to the corresponding wells at the corresponding positions of the microplate.

[0176] When the primary amine compound is a free alkyl primary amine and the compound contains n primary amine functional groups that can be converted to azide, 0.10 / n mmol of the primary amine is dissolved in 1.0 ml of 100 / n mM methanesulfonic acid solution (solvent is dimethyl sulfoxide) in a 1.5 ml centrifuge tube; if the compound contains two or more free basic functional groups (primary amine, secondary amine, tertiary amine, guanidine, etc.), the concentration of the methanesulfonic acid solution is increased to 200 / n mM. The prepared primary amine solution is then transferred to the corresponding wells of the corresponding microplate.

[0177] Primary amines with poor solubility in dimethyl sulfoxide can also be used to prepare azide compounds through diazo transfer, and most of these azide products can be dissolved in dimethyl sulfoxide and included in the azide compound library in the form of solution. However, these primary amines with poor solubility cannot be stored in the primary amine compound library in the form of solution. In addition to the 1128 primary amine compound libraries (distributed in 12 96-well microplates) stored in the form of solution in the microplate mentioned above, another 96 primary amines (some of which have poor solubility) were selected as substrates for diazo transfer. Thus, a library containing 1224 primary amines with different structures was constructed, which was used for the subsequent preparation of the azide compound library ( Figure 1 ).

[0178] Example 3 Preparation of azide compound library

[0179]

[0180] The fluorosulfonyl azide solution prepared by the method of Example 1 (the solvent is methyl tert-butyl ether, 19 F NMR measurement (about 400 mM concentration, about 40 ml) was diluted with dimethyl sulfoxide (40 ml) to obtain a fluorosulfonyl azide solution (by 19 F NMR measurement (about 200 mM concentration, 80 ml, solvent: dimethyl sulfoxide / methyl tert-butyl ether 1:1).

[0181] Using a 96-well pipette, transfer the primary amine solution (100 mM, solvent is dimethyl sulfoxide; take out 200 μl, containing 20 μmol primary amine) in each well of a 96-well plate in the primary amine compound library prepared in Example 2 to an empty 1.2 ml 96-well microplate. Add potassium bicarbonate aqueous solution (3.0 M, 26.7 μl, containing 80 μmol potassium bicarbonate) and the diluted fluorosulfonyl azide solution (200 mM, 100 μl, containing 20 μmol fluorosulfonyl azide) to each well. Add additional dimethyl sulfoxide (73 μl) to make the total volume about 400 μl. Seal the microplate and place it in a shaker, shaking at 800 rpm for 1 hour at 30°C. After shaking, each well in the microplate obtains a 50 mM concentration solution of the corresponding azide compound with a near quantitative yield (the solvent system is about dimethyl sulfoxide / methyl tert-butyl ether 3:1). The reaction solution in each well of the microplate is detected using UPLC-MS. An exemplary UPLC chromatogram is shown in FIG. Figure 2a -f as shown.

[0182] The compound library of 1128 primary amines in Example 2 obtained 1128 corresponding azide compounds by this method. The 1128 azide compound solutions were distributed in 12 96-well microplates (microplates numbered 1-7 and 10-14). The 96 primary amines stored separately in Example 2 (some of which have poor solubility) were reacted by the same method in this example to obtain 96 soluble azide compound solutions and transferred to a new 96-well microplate (see the 8th plate of the azide library for details). Thus, a compound library containing a total of 1224 azide solutions with different structures was established.

[0183] The compound library of 1224 azide solutions with different structures is distributed in 13 96-well microplates. The microplates of the azide compound library can be sealed and stored at a refrigerator temperature (4°C) and are stable for at least 6 months; the compound library can be used directly for reaction without separation.

[0184] The structure of the azide compound library and its position in the microplate are as follows, and the positions of the corresponding primary amine compound library (except the 8th plate) and triazole compound library remain unchanged.

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198] Example 4 Copper-catalyzed azide-terminal alkyne cycloaddition reaction (CuAAC) using azide compound library

[0199]

[0200] Sodium ascorbate (2.48 g, 12.5 mmol), disodium hydrogen phosphate (7.0 g, 49.3 mmol) and citric acid (4.87 g, 25.4 mmol) were mixed and dissolved in distilled water to 100 ml of aqueous solution to obtain a sodium ascorbate / disodium hydrogen phosphate / citric acid buffer solution with a pH value of about 5.

[0201] From the 8th plate of the azide compound library obtained in Example 2, a solution (100 μl, about 50 mM concentration, containing about 5 μmol azide) was taken out from each well and transferred to a new 350 μl 96-well plate. The above-mentioned ascorbic acid / sodium hydrogen phosphate / citric acid buffer solution (40 μl) was added to each well in turn, and the film was sealed and shaken at 800 rpm for 15 minutes at 30°C. The film was removed, and 3-acetamidophenylacetylene solution (compound 4a, 100 mM, solvent is dimethyl sulfoxide; 47.5 μl, containing 4.75 μmol 3-acetamidophenylacetylene) and copper sulfate / THPTA aqueous solution (copper sulfate and THPTA concentrations are 20 mM, 12.5 μl, 0.25 μmol) were added to each well. The microplate was sealed and stirred at 800 rpm at 40°C for 6 hours. After the reaction, the mixed solution in the plate was transferred one by one to an empty 1.2 ml 96-well plate. Methanol (400 μl) and acetonitrile (400 μl) were added to each well for dilution, and the generated 1,2,3-triazole product was detected using UPLC-MS.

[0202] UPLC chromatograms of exemplary 1,2,3-triazole products are shown in 3a-f.

[0203] Example 5: A primary amine compound library is used to directly obtain a 1,2,3-triazole compound library through diazo transfer and copper-catalyzed azide-terminal alkyne cycloaddition reaction (CuAAC).

[0204]

[0205] 50 μl (100 mM, solvent is dimethyl sulfoxide, containing 5 μmol primary amine) was taken out from each well of each 96-well plate in the 1128 primary amine compound libraries prepared in Example 2 (i.e., the primary amine compound structures corresponding to the azide compounds in plates 1-7 and 10-14 in Example 2) and transferred to the corresponding position in a new 96-well plate. Then, potassium bicarbonate aqueous solution (3.0 M, 6.7 μl, containing 20 μmol potassium bicarbonate), fluorosulfonyl azide solution (refer to Example 1, diluted to a solvent system of dimethyl sulfoxide / methyl tert-butyl ether 1:1; 200 mM, 25 μl, containing 5 μmol fluorosulfonyl azide) and dimethyl sulfoxide (18 μl) were added to each well in these new plates containing primary amine solutions in sequence, so that the total volume was about 100 μl. The 96-well plate was sealed with a film and shaken at 800 rpm at 30°C for 1 hour.

[0206] Sodium ascorbate (2.48 g, 12.5 mmol), disodium hydrogen phosphate (7.0 g, 49.3 mmol) and citric acid (4.87 g, 25.4 mmol) were mixed and dissolved in distilled water to 100 ml of aqueous solution to obtain a sodium ascorbate / disodium hydrogen phosphate / citric acid buffer solution with a pH value of about 5.

[0207] After shaking for 1 hour, the sealing film of the 96-well plate was torn off, and the sodium ascorbate / sodium hydrogen phosphate / citric acid buffer solution (40 μl) prepared above was added, and the sealing film was shaken at 800 rpm for 15 minutes at 30°C. After the sealing film was torn off, 3-acetamidophenylacetylene solution (compound 4a, 100 mM, solvent is dimethyl sulfoxide; 47.5 μl, containing 4.75 μmol 3-acetamidophenylacetylene) and copper sulfate / THPTA aqueous solution (copper sulfate and THPTA concentrations are 20 mM, 12.5 μl, 0.25 μmol) were added to each well. The microplate was sealed again and stirred at 800 rpm at 40°C for 6 hours. After the reaction, the mixed solution in the plate was transferred one by one to an empty 1.2 ml 96-well plate. Methanol (400 μl) and acetonitrile (400 μl) were added to each well for dilution, and the generated 1,2,3-triazole product was detected using UPLC-MS.

[0208] Exemplary UPLC chromatographic detection results are as follows: Figure 4a -i as shown.

[0209] Example 6: A primary amine compound library is used to directly obtain a 1,2,3-triazole compound library through diazo transfer and copper-catalyzed azide-terminal alkyne cycloaddition reaction (CuAAC).

[0210]

[0211] 50 μl (100 mM, solvent is dimethyl sulfoxide, containing 5 μmol primary amine) was taken out from each well of the second plate of the 1128 primary amine compound libraries prepared in Example 2 (i.e., the primary amine compound structures corresponding to the azide compounds in the 1st to 7th and 10th to 14th plates in Example 2) and transferred to the corresponding position in a new 96-well plate. Then, potassium bicarbonate aqueous solution (3.0 M, 6.7 μl, containing 20 μmol potassium bicarbonate), fluorosulfonyl azide solution (refer to Example 1, diluted to a solvent system of dimethyl sulfoxide / methyl tert-butyl ether 1:1; 200 mM, 25 μl, containing 5 μmol fluorosulfonyl azide) and dimethyl sulfoxide (18 μl) were added to each well of these new plates containing primary amine solutions in sequence, so that the total volume was about 100 μl. The 96-well plate was sealed with a film and shaken at 800 rpm at 30°C for 1 hour.

[0212] Sodium ascorbate (2.48 g, 12.5 mmol), disodium hydrogen phosphate (7.0 g, 49.3 mmol) and citric acid (4.87 g, 25.4 mmol) were mixed and dissolved in distilled water to 100 ml of aqueous solution to obtain a sodium ascorbate / disodium hydrogen phosphate / citric acid buffer solution with a pH value of about 5.

[0213] After shaking for 1 hour, the 96-well plate was sealed and the sodium ascorbate / sodium hydrogen phosphate / citric acid buffer solution (40 μl) was added. The sealing film was shaken at 800 rpm for 15 minutes at 30°C. After the sealing film was removed, 4-(4-pentynamido)phenyl fluorosulfonate solution (compound 4b, 100 mM, solvent is dimethyl sulfoxide; 47.5 μl, containing 4.75 μmol 3-acetylaminophenylacetylene) and copper sulfate / THPTA aqueous solution (copper sulfate and THPTA concentrations are 20 mM, 12.5 μl, 0.25 μmol) were added to each well. The microplate was sealed again and stirred at 800 rpm at 40°C for 6 hours. After the reaction, the mixed solution in the plate was transferred one by one to an empty 1.2 ml 96-well plate. Methanol (400 μl) and acetonitrile (400 μl) were added to each well for dilution, and the generated 1,2,3-triazole product was detected using UPLC-MS.

[0214] Exemplary UPLC chromatographic detection results are as follows: Figure 5a -d as shown.

[0215] The corresponding compounds of the azide compound library and triazole compound library prepared in Examples 1-6 were analyzed, and the results are summarized as follows: Figure 1 ):

[0216] (a) A search was performed in the Reaxys database, and 618 azide compounds were known and 606 azide compounds were novel.

[0217] (b) Among the 1224 addressable reactions, the reaction conversion rates of 656 reaction products (about 54%) were greater than 90%; the reaction conversion rates of 333 reaction products (about 27%) were between 70% and 90%; the reaction conversion rates of 144 reaction products were between 30% and 70%; the reaction conversion rates of 17 reaction products were less than 30%; and the UPLC chromatographic detection peaks of 74 reaction products overlapped with the peak of 3-acetamidophenylacetylene, and the conversion rates could not be calculated.

[0218] The above results show that almost all addressable reactions obtained the corresponding expected reaction products, among which at least 989 (989 / 1224=80.8%) addressable reactions had a conversion rate of more than 70%, thus fully meeting the relevant requirements of subsequent biological activity tests.

[0219] The identification results of some of the compounds generated in the 1224 addressable reactions performed in the reaction chamber are shown in Figures 3, 4 and 5.

[0220] In summary, unexpectedly, through the method of the present invention, a specific synthetic reaction can be independently carried out in each reaction chamber, thereby efficiently and high-throughputly preparing a large number of different reaction products with clear structures, and thus obtaining a high-throughput compound library. Therefore, the addressable reaction chamber array (or the corresponding compound library) containing the reaction products can be directly used for subsequent compound activity determination in situ without separation and purification.

[0221] Example 7 Construction of a library of 840 erlotinib derivatives

[0222]

[0223] The overall reaction formula is shown above, and the operation steps are as follows:

[0224] (1) Add 37 μL DMSO, 13 μL H2O, 10 μL azide building block in DMSO solution (50 mM) and 20 μL erlotinib in DMSO solution (25 mM) to each well of a 96-well plate and mix well.

[0225] (2) Add 5 μL of copper sulfate aqueous solution (5 mM), 5 μL of tris[(1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)]methyl]amine aqueous solution (5 mM) and 10 μL of sodium ascorbate aqueous solution (250 mM) to each well of a 96-well plate, and shake at room temperature for 12 hours.

[0226] There were 9 96-well plates in total, 840 samples (final concentration: 5 mM, final volume: 100 μL). UPLC-MS randomly tracked some samples and showed that the conversion rate of most samples was above 70%, and they were directly used for MTT screening.

[0227] MTT method was used to screen 840 Erlotinib derivatives. The operation steps are as follows:

[0228] (1) A549 (lung cancer) cells adhered overnight: cells in the logarithmic growth phase were taken, digested and counted, and 5,000 cells per well were plated in a 96-well plate overnight.

[0229] (2) Drug addition: dilute the compound to a concentration of 10 μM with complete culture medium, discard the supernatant, and administer the drug at a volume of 100 μL per well for 24 hours.

[0230] (3) Add MTT: Add 20 μL MTT (5 mg / mL) to each well and incubate for 4 hours.

[0231] (4) Measure absorbance: discard the supernatant, add 150 μL of DMSO to each well, shake on a shaker for 10 minutes to fully dissolve the crystals. Measure the absorbance of the solution at 570 nm using an enzyme-labeled instrument.

[0232] The relative survival rate was calculated as follows: it refers to the ratio of the survival rate of cells treated with erlotinib derivatives to the survival rate of cells treated with the positive compound (erlotinib), wherein the lower the relative survival rate, the better the activity of the compound.

[0233] Experimental results:

[0234] The results are as follows Figure 6 As shown: From 840 compounds, 265 compounds with higher activity than Erlotinib (relative survival rate <1) were screened on A549 cells, of which 19 compounds had better activity (relative survival rate <0.5).

[0235] Compounds selected from multiple 96-well array reactors with exemplary partial activities for each addressable reaction chamber that are better or slightly better than the positive compound (Erlotinib) are listed in Tables 1 and 2 below:

[0236] Table 1 Structures and biological activities of some compounds in the high-throughput compound library (relative survival rate = 0.5-1)

[0237]

[0238]

[0239]

[0240]

[0241] Table 2 Structures and biological activities of some compounds in the high-throughput compound library (relative survival rate > 1)

[0242]

[0243]

[0244] The results show that the method of the present invention can complete the preparation and screening process of the compound in the same reaction system (or reaction chamber). Since both steps of the reaction generate products almost quantitatively, the products can be used in enzymology and even cytology test experiments without separation, which has important application value in the field of high-throughput synthesis and screening of compounds.

[0245] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A method for high-throughput compound library construction and screening, characterized in that: include: (a) providing a reactor, the reactor comprising n reaction chambers, wherein the reaction chambers are each independent and addressable, and the n reaction chambers constitute an addressable reaction chamber array; (b) performing m independent synthesis reactions in the n reaction chambers, and obtaining synthesis products in each reaction chamber for performing the synthesis reaction, thereby constructing a compound library; Wherein, the synthetic reaction comprises the following steps: (b1) in a reaction chamber, in an inert solvent, reacting a 1,3-dipolar cyclization reagent with a reaction substrate containing a terminal unsaturated bond to undergo a 1,3-dipolar cycloaddition reaction to form a reaction product containing a 1,3-dipolar ring; and (c) optionally, adding activity test reagents to the reaction chambers where the synthesis reaction is performed, respectively, to perform activity tests, thereby performing activity screening on each synthesis product; Wherein, n is a positive integer ≥10, m is a positive integer ≤n and m≥10; The step (b), before step (b1), further comprises: (b0) reacting an amine fragment R-NH2 with FSO2N3 in an inert solvent in the presence of a base to prepare a 1,3-dipolar cyclization reagent; Wherein, R is a molecular part (moiety) or a fragment connected to the azide group; In the step (b), the reaction formula of the 1,3-dipolar cycloaddition reaction is selected from the following group: In the formula, R, R', R" and R"' are each independently R 1 or The R 1 and R 2 Each is independently a substrate fragment; The R 1 and R 2 Each is independently substituted or unsubstituted and is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, heterocyclyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaromatic, sulfonyl, or a combination thereof.

2. The method according to claim 1, characterized in that The volumes of the reaction chambers are independently 5 μL-5000 μL.

3. The method according to claim 1, characterized in that The activity test reagent is selected from the following group: small molecule compounds, proteins, nucleic acids, cells or a combination thereof.

4. The method according to claim 1, characterized in that The step (c) includes the step of detecting each reaction chamber, thereby obtaining the activity test results in each chamber respectively.

5. The method according to claim 1, characterized in that The steps between steps (b) and (c) do not include a step of separating or purifying the reaction product.

6. The method according to claim 1, characterized in that The method further comprises: The data of the reaction substrate, reaction product and activity test are associated based on the addressable addresses of the reaction chamber to obtain an addressable data set.

7. The method according to claim 1, characterized in that The R 1 and R 2 Each independently selected from the following group: substituted or unsubstituted C1-C 12 alkyl, substituted or unsubstituted 3-12 membered heteroalkyl, substituted or unsubstituted 5-16 membered heteroaryl, substituted or unsubstituted C6-C 18 aryl, substituted or unsubstituted 3-20 membered heterocyclic group, substituted or unsubstituted C3-C 12 wherein the substitution refers to that one or more hydrogen atoms in the group are replaced by a substituent Ra, and the Ra is selected from the group consisting of halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C 12 Cycloalkyl, oxo (i.e., =O), Rf-SO2-, =NRf, -CN, hydroxyl, -ORf, NRdRe, substituted or unsubstituted C1-C6 amine, substituted or unsubstituted -(C1-C6 alkylene)-NH-(C1-C6 alkylene), carboxyl, substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted 5-12-membered heteroaryl having 1-3 heteroatoms, substituted or unsubstituted 5-12-membered heterocyclic group having 1-4 heteroatoms, wherein the substituent is selected from the following group: halogen, hydroxyl, carboxyl, cyano, C1-C6 alkoxy, C1-C6 alkylamino; Rd, Re, and Rf are each independently selected from the group consisting of H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted 5-12-membered heteroaryl having 1-3 heteroatoms, substituted or unsubstituted 5-12-membered heterocyclyl having 1-4 heteroatoms; The "substituted" of Rd, Re, and Rf refers to being substituted by one or more substituents selected from the following groups: halogen, -CH2Cl, -CHCl2, -CCl3, -CH2F, -CHF2, -CF3, -O(CH2) x O(CH2) y CH3, oxo, -CN, hydroxyl, amino, substituted amine, carboxyl, -NHAc, a group selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C6-C 10 Aryl, C3-C8 cycloalkyl, halogenated C6-C 10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; x is 1, 2, 3, 4, 5, or 6; y is 0, 1, 2, 3, 4, 5, or 6; In the above formulae, any of the heteroatoms are independently selected from the group consisting of N, S and O.

8. The method according to claim 1, characterized in that In step (b), the inert solvent is selected from the group consisting of water, nitrile solvents, alcohol solvents, aromatic hydrocarbon solvents, halogenated alkane solvents, sulfur dioxide, alkane solvents, ester solvents, ketone solvents, ether solvents, sulfoxide solvents, amide solvents or combinations thereof.

9. The method according to claim 1, characterized in that In step (b), the base is an inorganic base and / or an organic base.

10. The method according to claim 1, characterized in that In the step (b0), m different amines located in m reaction chambers are used to react with FSO2N3 respectively, so as to obtain different R-N3.

11. The method according to claim 1, characterized in that The molar ratio of R-NH2 to FSO2N3 is 1:2 to 2:

1.

12. The method according to claim 1, characterized in that The molar ratio of R-NH2 to FSO2N3 is 1:

1.

13. The method according to claim 1, characterized in that The molar ratio of the alkali to FSO2N3 is 10:1 to 2:

1.

14. The method according to claim 1, wherein: The molar ratio of the alkali to FSO2N3 is 4:1.

Citation Information

Patent Citations

  • High throughput screening method for antimicrobial compounds and application of high throughput screening method

    CN103421876A

  • Methods for prodn. ef large catalogued chemical libraries

    CN1173921A